Viewing nowJanuglyptin Tablets 100 mg (Sitagliptin Phosphate)
Sitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Dasan Pharmaceutical Co., Ltd.

MFDS item code 201503180 · Approved 2015.05.27 · Insurance code 678600520
Improvement of glycemic control in patients with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapy to help control blood sugar levels in patients with type 2 diabetes. It is initially administered as monotherapy, but in cases where the patient has not received previous diabetes treatment or has difficulty controlling blood sugar with monotherapy, it is used in combination with metformin. Additionally, if blood sugar control is inadequate with monotherapy using sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is used as an adjunctive therapy. This medication is also added when blood sugar control is insufficient despite the use of multiple agents. It effectively assists in the management of the patient's blood sugar and improves blood sugar control.
This drug is administered at 100 mg once daily as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This drug may be taken without regard to meals. When coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, section 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is required, assessment of renal function is recommended before and periodically during treatment with this drug. 1. No dose adjustment is required in patients with mild renal impairment (estimated glomerular filtration rate [eGFR] ≥ 60mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is required in patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 45mL/min/1.73 m2 and < 60mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥ 30mL/min/1.73 m2 and < 45mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (estimated glomerular filtration rate [eGFR] ≥ 15mL/min/1.73 m2 and < 30mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (estimated glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This drug may be administered regardless of the timing of dialysis.
This medication may cause severe allergic reactions; if symptoms such as hives or skin rash, difficulty breathing occur, take it immediately and consult a doctor. While taking this medication, symptoms of acute pancreatitis, which is inflammation of the pancreas, may occur, so alert medical personnel immediately if there are symptoms such as abdominal pain or vomiting. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, nor in those allergic to this drug or its components. Patients with impaired renal function need dose adjustment; hence, regular kidney function tests should be conducted, and dosage should be followed according to the physician's instructions. During treatment, side effects such as cold symptoms, headache, indigestion, and diarrhea may occur, and caution should be exercised as the risk of hypoglycemia may increase, particularly in combination with insulin or sulfonylureas. This medication can cause hypoglycemic symptoms when used with other blood sugar-lowering agents, so dosage adjustment may be needed if necessary. If severe arthralgia or blistering skin symptoms occur, notify a doctor immediately and discontinue the medication if necessary. Pregnant or breastfeeding women are advised not to take this medication, and safety and efficacy in children or adolescents under 18 years have not been established. Elderly patients may have reduced kidney function, so kidney function should be monitored before and after administration, and dosage adjustments may be required. In case of overdose, the drug should be removed from the gastrointestinal tract, and the patient's condition must be closely monitored, including electrocardiogram tests, and blood dialysis may be performed if necessary. This medication has fewer interactions with other drugs, but caution is required when combined with specific medications, so all currently administered drugs should be disclosed to the medical personnel.
Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory tract infections, headache, diarrhea, abdominal pain, nausea, peripheral edema, constipation, vomiting, arthralgia accompanied by severe and disability, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetic complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased serum triglycerides, gastritis, elevated low-density lipoprotein, hyperglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly sealed container to prevent the ingress of air or moisture, and it should be kept at a temperature between 1 and 30 degrees Celsius. Proper storage will help maintain the medication's effectiveness for a longer period.
Beige, round, biconvex film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Phosphate 124.08mg
Tablet · Prescription medication
Dasan Pharmaceutical Co., Ltd.

Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Jongkeundang Co., Ltd.

Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Sitagliptin Phosphate Hydrate 32.13mg
Tablet · Prescription medication
Jong Kundang Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication
Vivozon Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.
Sitagliptin Phosphate Hydrate 32.125mg
Tablet · Prescription medication
Sinpoong Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.